Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| And so we are optimistic that those data are going to continue to look good |
| Together, we expect these multiple steps to provide a strong financial base on which we may continue to invest in our core programs, and new innovations |
| There's also a cost management side to creating a strong financial base |
| The data we presented at AHA in November on zodasiran's ability to reduce remnant cholesterol which is believed to be a major contributor to the residual risk of ASCVD after LDL cholesterol is well controlled was very encouraging |
| Both zodasiran and plozasiran are really incredibly good drugs from a pharmacologic perspective |
| I think our revised budget puts us in a stronger position strategically, as well as financially |
| It is more commercially attractive than ARO-SOD1, while still serving as a good proof-of-concept for the CNS platform |
| There are only about 16,000 pulmonologists in United States and we believe it's an attractive prospect to build a specialized commercial sales organization to support a growing pipeline of medicines that addresses various respiratory diseases |
| We liked ARO-SOD1, we liked the opportunity because it gave us a good chance to interrogate the platform |
| Together, these set up an attractive opportunity |
| We have a high degree of confidence that this will be a powerful drug for this patient population with very high unmet medical needs |
| This is encouraging and consistent with our expectations of a properly designed RNAi therapeutic that leverages our proprietary TRiM platform |
| We believe it will be a powerful and welcomed leap forward for patients |
| It was substantially oversubscribed and saw a terrific participation from high quality investors |
| It gives us good proof-of-concept of platform, but also will be a more commercially viable drug |
| That's the good news |
| We're excited about seeing those data |
| That transaction was confidentially marketed to just a handful of funds and we were pleased with the result |
| Plus plozasiran has demonstrated best-in-class data at each prior step of the clinical development process |
| As you know, we have a very robust pipeline of early clinical stage programs, and even more even more robust pipeline of discovery stage programs, most of which we haven't disclosed yet |
| Plozasiran has been generally well-tolerated and consistently did what it was designed to do |
| One is based on our adipose targeting TRiM platform, which has shown impressive preclinical data |
| It's great to be back helping Arrowhead move forward in the most effective and efficient way possible |
| This is an exciting time, and I'm thrilled to be back and to be part of this next big milestone for Arrowhead |
| These are promising programs |
| We are achieving these estimates, while importantly, continuing to fully fund our core pulmonary and cardiometabolic verticals and innovative new technologies and programs |
| This commitment to creating a large number of new medicines as quickly as we can, speaks to our dual mandate; to maximize number of patients, we can help and to maximize our ability to create durable value for our shareholders |
| This is exemplified by our '20 and '25 initiatives, where we expect to grow our pipeline of RNAi Therapeutics to at least 20 clinical stage or marketed products by the year 2025 |
| Third, we intend to continue to strengthen our balance sheet with a structured finance transaction and one or more business development transactions |
| There is currently no FDA-approved therapy that lowers triglycerides than more than 20% or 30% and plozasiran has been generally well-tolerated in prior studies |
| Statement |
|---|
| Ken will talk about specifics in a moment, but we're reducing our guidance on fiscal year operating burn by approximately $100 million |
| And so it was less of SOD1 failing than a lack of confidence in the SOD1 ALS market |
| In addition, ARO-SOD1 our CNS candidate against SOD1 ALS will not move forward |
| And fifth, we are not done innovating |
| These patients have inadequate treatment options, and we believe that plozasiran could represent a significant leap forward |
| It is yet unproven in clinical trials because frankly, there just haven't been good enough drugs for treating these and so it has been untestable |
| It just was not as strong as the inhaled version |
| The problem with SOD1 is that it was becoming -- it was appearing to be increasingly commercially unviable |
| This is a severe disease of extremely high triglyceride levels that puts patients at high risk of episodes of severe abdominal pain, acute pancreatitis, hospitalization, and it can be fatal |
| FSHD is an autosomal dominant disease associated with the failure to maintain complete epigenetic suppression of DUX 4 expression in differentiated skeletal muscle |
| But ultimately, we have to prove it |
| I can tell you that, that what we've seen so far, it's still an incomplete data set |
| But again, but it did work |
| We have revised our budget to reflect an anticipated reduction in growth of our spend over this fiscal year and beyond |
| Our portfolio review also affected some undisclosed preclinical programs |
| They are the visceral fat stores shrinking, what happens to lean mass |
| It is difficult to overstate the importance of our cardiometabolic vertical in driving our value proposition |
| We know that elevated triglyceride levels in certain patient populations can lead to severe abdominal pain, acute pancreatitis, hospitalizations and other difficult downstream effects and even in rare cases, death |
| So does this mean that we will slow down or stop early development outside our focus areas? It does not |
| We just weren't seeing as deep a knockdown as we've seen with the inhaled |
Please consider a small donation if you think this website provides you with relevant information